Breastfeeding warning
Use during breastfeeding only on medical advice.
Medicine information ABACAVIR/LAMIVUDINA VIATRIS 600mg / 300mg film-coated tablets
- Product code:
- W69243001
- Quantity:
- 30
- Indicated for:
- HIV-1 infection
- Route of administration:
- oral
- Substance:
- abacavir + lamivudine (nucleoside/nucleotide reverse transcriptase inhibitors)
- ATC
- J05AR02 — Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections, combinations
Abacavir and lamivudine are antiretroviral medications used in combination for the treatment of HIV-1 (human immunodeficiency virus) infection. They belong to the class of nucleoside reverse transcriptase inhibitors (NRTIs), working by blocking the reverse transcriptase enzyme, which is essential for HIV replication.
This combination is used as part of antiretroviral therapy (ART) to reduce viral load, increase CD4 cell count, and slow the progression of the disease. It is crucial to take the medication as prescribed, without interruptions, to prevent the development of viral resistance.
Side effects may include nausea, fatigue, headaches, or, more rarely, hypersensitivity reactions to abacavir, which can be severe and require immediate discontinuation of treatment. Genetic testing for the HLA-B*5701 allele is recommended before starting therapy, as its presence is associated with an increased risk of allergic reactions to abacavir.
This combination is effective in managing HIV infection but does not cure the disease. Patients must adhere to long-term treatment and maintain regular health monitoring.
This combination is used as part of antiretroviral therapy (ART) to reduce viral load, increase CD4 cell count, and slow the progression of the disease. It is crucial to take the medication as prescribed, without interruptions, to prevent the development of viral resistance.
Side effects may include nausea, fatigue, headaches, or, more rarely, hypersensitivity reactions to abacavir, which can be severe and require immediate discontinuation of treatment. Genetic testing for the HLA-B*5701 allele is recommended before starting therapy, as its presence is associated with an increased risk of allergic reactions to abacavir.
This combination is effective in managing HIV infection but does not cure the disease. Patients must adhere to long-term treatment and maintain regular health monitoring.
General data about ABACAVIR/LAMIVUDINA VIATRIS 600mg / 300mg
- Substance:
- abacavir + lamivudine
- Date of latest medicines list:
- 01-10-2026
- Product code:
- W69243001
- Strength:
- 600mg / 300mg
- Pharmaceutical form:
- film-coated tablets
- Quantity:
- 30
- Product type:
- Generic medicine
- Price:
- 663.04 RON
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Combinations with other substances
Official documents
Warnings:
Pregnancy warning
Use during pregnancy only on medical advice.
Severe skin reactions
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Genetic test recommended
A genetic test may be needed before treatment.
Reimbursement lists for ABACAVIR/LAMIVUDINA VIATRIS 600mg / 300mg Viatris
NHP 1.A (C2) - People with HIV/AIDS and post-exposure treatment
- Price
- 663.04 RON
- Copayment
- 345.16 RON
- Patient payment
- 317.88 RON